Current Partners

The following list of partners represents a selection of our current collaborations. Announcements of additional collaborations are located in the News section of this website at http://www.asahikasei-pharma.co.jp/en/news/.

SBI Biotech Co., Ltd.

In March 2020, SBI Biotech Co., Ltd. granted Asahi Kasei Pharma the exclusive worldwide rights to develop, manufacture, and market SBI-3150, which is currently in the pre-clinical stage as a treatment for various autoimmune diseases. SBI-3150 is a monoclonal antibody that recognizes phospholipase D family member 4 (PLD4), which is specifically expressed by plasmacytoid dendritic cells (pDCs)1 and activated B-cells2, leading to immune suppression.

Woolsey Pharmaceuticals

ERIL™
In June 2019, Asahi Kasei Pharma granted Woolsey Pharmaceuticals exclusive rights to develop and commercialize any formulations (other than ophthalmic and injectable forms) of fasudil hydrochloride hydrate, a rho-kinase inhibitor, in the USA, Europe, and all other territories outside of Japan, China, South Korea, and Taiwan. Asahi Kasei Pharma hopes that its license agreement with Woolsey will enable fasudil to contribute to the treatment of rare neurodegenerative diseases for the benefit of more patients around the world.

Basilea Pharmaceutica International Ltd.

In September 2016, Basilea Pharmaceutica International granted Asahi Kasei Pharma exclusive rights in Japan to develop and commercialize isavuconazole (AK1820) for invasive fungal infections including aspergillosis and mucormycosis.

Orion Corporation

In June 2016, Asahi Kasei Pharma and Orion entered into a global strategic collaboration agreement for the discovery, development, and commercialization of new pain management therapies. Four discovery phase candidates, two provided by each company, are subject to joint development under a global strategic collaboration agreement. Asahi Kasei Pharma and Orion have the right to exclusively license the other's development-ready programs, with all development costs to be shared by both companies. Asahi Kasei Pharma will have exclusive marketing rights in East Asia, Southeast Asia, and South Asia excluding Afghanistan and Pakistan, while Orion will have exclusive marketing rights in Europe and Central Asia. The optimal marketing configuration for other territories will be determined through mutual discussion between Asahi Kasei Pharma and Orion.

Array BioPharma Inc.

In March 2016, Asahi Kasei Pharma and Array BioPharma entered into a strategic collaboration to develop and commercialize select tropomyosin receptor kinase A (TrkA) inhibitors, AK1830 (ARRY-954) for pain, inflammation, and other non-cancer indications. Asahi Kasei Pharma will have rights to develop and exclusively commercialize products in Japan, Korea, Taiwan, and China for pain, inflammation, and other non-cancer indications.

PeptiDream Inc.

In March 2016, Asahi Kasei Pharma announced that it had entered into a joint R&D agreement with PeptiDream for the discovery and development of nonstandard peptides against multiple drug target molecules using PeptiDream's proprietary Peptide Discovery Platform System, which enables the rapid artificial generation of nonstandard peptide libraries and the efficient identification of nonstandard peptides.

Dong-A ST Co., Ltd.

TERIBONE™
In December 2014, Asahi Kasei Pharma granted Dong-A ST exclusive rights in Korea for the development and sale of Teribone™ (teriparatide acetate) for the treatment of osteoporosis in postmenopausal women at high risk of bone fracture. Teribone™ was launched in Korea in March 2016.

FLIVAS™
In April 2009, Asahi Kasei Pharma granted Dong-A ST exclusive rights in Korea for the development and sale of Flivas™ (naftopidil) for the treatment of benign prostatic hyperplasia (BPH). Flivas™ was launched in Korea in January 2012.

RaQualia Pharma Inc.

Under a research collaboration agreement started in November 2013, Asahi Kasei Pharma and RaQualia Pharma have engaged in research to discover candidate compounds against P2X7 receptor for pain treatment. In March 2018, Asahi Kasei Pharma obtained exclusive rights for the worldwide development, manufacture, and sale of P2X7 receptor antagonist, AKP-23494954/RQ-00466479, and is responsible for the development of this program.

Endo International plc

In March 2011, Asahi Kasei Pharma was granted exclusive rights in Japan to develop and market Xiaflex® (collagenase clostridium histolyticum), a biologic developed to provide a nonsurgical treatment option for Dupuytren's contracture and Peyronie's disease. Xiaflex® was launched in Japan for Dupuytren's contracture in September 2015.

Novartis Pharma AG

RECLAST®
In June 2010, Novartis Pharma granted Asahi Kasei Pharma exclusive rights in Japan to develop and market the bisphosphonate agent Reclast® (zoledronic acid) for the treatment of osteoporosis. Reclast® was approved in Japan in September 2016.

FAMVIR®
Pursuant to an agreement restated in 2008, Asahi Kasei Pharma was granted rights in Japan to distribute the anti-herpes virus drug Famvir® (famciclovir) for the indications of herpes zoster (shingles) and herpes simplex. Famvir® was launched in Japan for herpes zoster in July 2008 and approved for herpes simplex in February 2013.

Page Top